CardiaCare closes seed extension funding

CardiaCare secures funding led by Solardis Health Ventures to expand its cardiac arrhythmia treatment technology and help physicians monitor patients remotely.

CardiaCare, an Israeli medical device company, has successfully closed a seed extension financing round. This financing was led by Solardis Health Ventures. The goal of the funding is to further develop CardiaCare's technology for the detection and treatment of cardiac arrhythmias, particularly atrial fibrillation (AFib).

The signed closing of this round reflects the potential of CardiaCare's technology to change the standard of care for atrial fibrillation. We are proud to have Solardis Health Ventures on the team along with accomplished clinical and commercial leaders.

Ofer Halbreich, CEO CadiaCare

CardiaCare's technology enables the detection, monitoring and non-invasive treatment of cardiac arrhythmias using drug-free neuromodulation. The platform is designed to help physicians remotely monitor their patients and enable personalized neuromodulation treatments based on real-time patient data.

Solardis Health Ventures is proud to lead this round and support CardiaCare's mission to become the first therapeutic wearable for patients with cardiac arrhythmias.

Amir Soltanianzadeh, Founder & Managing Partner of Solardis Health Ventures

Funds from the financing round will be used to support existing and future clinical trials of the clinical efficacy of CardiaCare's therapy for various indications. CardiaCare's mission is to become the standard of care platform for patients with cardiac arrhythmias. The company was founded by heart rhythm specialist and entrepreneur Amos Ziv.